Skip to main content

CORRECTION article

Front. Oncol., 05 April 2023
Sec. Radiation Oncology

Corrigendum: Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure

Justin LeuJustin Leu1Meredith AkermanMeredith Akerman2Christopher MendezChristopher Mendez3Jonathan W. Lischalk,Jonathan W. Lischalk3,4Todd CarpenterTodd Carpenter3David EblingDavid Ebling3Jonathan A. Haas,Jonathan A. Haas3,4Matthew WittenMatthew Witten5Marissa BarbaroMarissa Barbaro6Paul DuicPaul Duic6Lee TesslerLee Tessler7Michael C. Repka*Michael C. Repka8*
  • 1Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States
  • 2Division of Health Services Research, New York University (NYU) Long Island School of Medicine, Mineola, NY, United States
  • 3Department of Radiation Oncology, Perlmutter Cancer Center at New York University (NYU) Long Island, Mineola, NY, United States
  • 4NYCyberKnife at Perlmutter Cancer Center – Manhattan, New York, NY, United States
  • 5Department of Medical Physics, Perlmutter Cancer Center at New York University (NYU) Long Island, Mineola, NY, United States
  • 6Department of Neurology, New York University (NYU) Long Island School of Medicine, Mineola, NY, United States
  • 7Department of Neurosurgery, Perlmutter Cancer Center at New York University (NYU) Long Island, Mineola, NY, United States
  • 8Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, United States

A corrigendum on
Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure

by Leu J, Akerman M, Mendez C, Lischalk JW, Carpenter T, Ebling D, Haas JA, Witten M, Barbaro M, Duic P, Tessler L and Repka MC (2023). Front. Oncol. 13:1132777. doi: 10.3389/fonc.2023.1132777

Text Correction

In the published article, there was an error. One of the citations of Table 3 was incorrect and should have referred to Table 4 instead.

A correction has been made to the Results section, Association between regional failure (distant brain failure) and other variables, paragraph 1. This sentence previously stated:

“After univariate analyses, age at diagnosis, histology, MRI maximum axial dimension, time interval between diagnostic MRI and first treatment, time interval between CT simulation and first treatment, fractionated versus single fraction SRS, total dose, GTV, PTV, max GTV dose, presence of normal brain constraint, and a history of prior WBRT were not associated with regional failure (Table 3).”

The corrected sentence appears below:

“After univariate analyses, age at diagnosis, histology, MRI maximum axial dimension, time interval between diagnostic MRI and first treatment, time interval between CT simulation and first treatment, fractionated versus single fraction SRS, total dose, GTV, PTV, max GTV dose, presence of normal brain constraint, and a history of prior WBRT were not associated with regional failure (Table 4).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: stereotactic radiosurgery, brain metastases, immunotherapy, radionecrosis, treatment delays, cancer, radiation therapy, radiation necrosis

Citation: Leu J, Akerman M, Mendez C, Lischalk JW, Carpenter T, Ebling D, Haas JA, Witten M, Barbaro M, Duic P, Tessler L and Repka MC (2023) Corrigendum: Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure. Front. Oncol. 13:1192726. doi: 10.3389/fonc.2023.1192726

Received: 23 March 2023; Accepted: 29 March 2023;
Published: 05 April 2023.

Edited and Reviewed by:

John Varlotto, Edwards Comprehensive Cancer Center, United States

Copyright © 2023 Leu, Akerman, Mendez, Lischalk, Carpenter, Ebling, Haas, Witten, Barbaro, Duic, Tessler and Repka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Michael C. Repka, michael_repka@med.unc.edu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.